PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
News|Articles|May 24, 2016
Evercyte and VTU Launch Recombinant Media Supplement
Author(s)Pharmaceutical Technology Editors
The companies have launched VEGF 165, their first joint product for cell culture applications.
Advertisement
Evercyte GMbH and VTU Technology have entered into a collaboration agreement on the development of recombinant media supplements for cell culture applications and launched their first conjointly developed recombinant product, according to a May 24, 2016
The Evercyte and VTU collaboration will allow the companies to develop recombinant media supplements, including growth factors and cytokines. Recombinant products will be produced by VTU based on its proprietary Pichia technology, facilitating the manufacturing of media supplements.
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Advertisement
Advertisement